The analysis indicated a significantly higher expression level of IRF9 and XRCC1 in PsP (diagnosis for pseudoprogression) cases than those for the true tumor progression (TTP) patients in both private and TCGA/TCIA data. The gene discussed is IRF9; the disease is supranuclear palsy, progressive, 1.